In the last few years, Mundipharma has been on a transformational journey. As part of this, we have redefined our focus and put the patient at the centre of all that we do. As we evolve into a specialty care focussed company, we strive to ensure access and optimal healthcare solutions for patients around the world.
Focusing on patients and the healthcare professionals who support them is vital to achieving patient-centricity. It requires the right approach, the right structure and the right people and skills. To enable this, Mundipharma changed its Global Commercial organisational structure to amplify and hone the value we bring in a meaningful and impactful way for patients.
To support our new Global Commercial structure, our strategic functional partners in Scientific Affairs, Finance & IT, Compliance, Technical Operations, Quality, Legal, People and Communications & Corporate Affairs have realigned to foster an environment of partnership, collaboration and enhanced customer and patient focus. Their collective expertise ensures a holistic approach to delivering innovative solutions for patients. Our functional partners provide critical insights, helping to maximise patient access to treatment.
Mundipharma united for patients.
One global company, four clusters, two countries
At Mundipharma, our Global Commercial team is structured into four clusters and two countries defined according to their dedicated therapeutic areas and focus. In this way, we can provide a dedicated and tailored offering to ensure that our customers, stakeholders and partners have what they need to ensure patients receive treatment when it matters most.
Growth brands and established portfolio
In 2025, we will provide medicines to more than an estimated 18.5 million patients1. Our medicines and therapeutic areas include anti-infectives, oncology, pain management, biosimilars, respiratory, central nervous system (CNS) and ophthalmology.
Within Global Commercial we focus primarily on three growth brands: our anti-infective REZZAYO® ▼ (rezafungin), and our Central Nervous System treatments Foquest® (methylphenidate) and Anerem® (remimazolam).*
We also have an ongoing commitment to deliver our established portfolio to support healthcare professionals in providing treatments that many benefit patients, depending on individual needs and clinical circumstances. Established products enable healthcare professionals to help millions of patients around the world each year.
Mundipharma United for Patients
Our transformation was an important and iterative process, accomplished in an extremely short time which is a testament to the colleagues and teams we have here at Mundipharma. We redefined and optimised our business, creating a unique, nimble and impactful organisation with patient centricity at the heart of all we do.
Our new mission – united for patients –ensures that we all continue to dedicate our efforts to patient access and outcomes.
We are well positioned to ensure a sustainable future with reliable access to healthcare and medicines when it matters most.
The next chapter
Now our Global Commercial structure is in place, our attention and efforts at Mundipharma have broadened to enhance Operational Excellence. Vital to ensuring we consistently deliver the right product to the right patient at the right time, and guided by our values — unique, nimble, impactful —we endeavour to continuously optimise how we work together. This commitment enables us to simplify and focus our efforts to deliver impactful outcomes for all.
We have designed and launched Operational Excellence initiatives to optimise how we work, strengthen collaboration, and deliver measurable results that support our efforts to improve patient experience and outcomes. Together, these programmes will form the foundation for a more sustainable, efficient, and patient-centered future as we continue along the change continuum.
At Mundipharma we are united for patients.
Petra Molan
Chief Commercial Officer
1 The number of estimated patients was calculated based on a standard IQVIA methodology, combining Ex Factory volume with IQVIA supplied metrics for adherence, daily dosage and treatment duration.
*This list is not exhaustive and in order to comply with regulations, we are unable to provide detailed product information. Not all products are available in all markets. Additionally, currently approved indications and presentations may differ between countries. Please always ask a healthcare professional for advice regarding medicines.
Job code: SciA-ANE-2500002
Date of preparation: May 2025